Overview

5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Low Anterior Resection Syndrome(RALARS)

Status:
Not yet recruiting
Trial end date:
2032-12-01
Target enrollment:
Participant gender:
Summary
5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Low Anterior Resection Syndrome(RALARS): Multicenter Randomized Controlled Trial
Phase:
N/A
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Ramosetron